An INR of 3.2 can trigger two reflexes in an older patient with acute cholangitis: reverse warfarin before any procedure, or ignore the anticoagulation because drainage is urgent. Neither response starts with the right question: What does the procedure need to accomplish now—decompress the infected duct, or also cut the papilla and extract the stone?
Consider an illustrative case of a 78-year-old woman with fever, confusion, hypotension, acute kidney injury, jaundice, and a dilated common bile duct with a suspected distal stone. She takes warfarin for permanent atrial fibrillation. Antibiotics, resuscitation, and urgent gastroenterology involvement proceed in parallel. Her confusion, hypotension, and kidney injury signal organ dysfunction and strengthen the need for timely source control. The anticoagulation decision should be matched to the intervention needed—not to the word ERCP alone.
First define the procedure, not just the INR
Biliary decompression and definitive stone clearance are related but separable goals. When technically feasible, an endoscopist may cannulate the bile duct and place a temporary stent or nasobiliary drain without performing a sphincterotomy. That may relieve obstruction while postponing stone extraction until the patient’s condition and anticoagulation plan are better controlled.
The distinction matters because procedural bleeding risk differs. BSG/ESGE endoscopy guidance categorizes biliary stenting as low risk and ERCP with sphincterotomy as high risk. These categories distinguish procedures; they do not, by themselves, establish that a particular INR is acceptable or eliminate patient-specific risks.
| Procedural goal | Typical approach | Why it matters here |
|---|---|---|
| Decompress the duct | Stent or nasobiliary drainage, when technically feasible | May provide urgent source control without a papillary incision |
| Clear the duct stone | Often requires sphincterotomy and stone extraction | Adds bleeding risk and may be better staged if immediate clearance is not essential |
| Drainage after unsuccessful endoscopic access | Consider an alternative drainage route with the relevant specialist teams | Percutaneous or EUS-guided approaches have their own risks; neither should be assumed safer in anticoagulation or coagulopathy |
Drainage-only ERCP is not the default for every patient with cholangitis. ASGE guidance conditionally favors combining drainage with sphincterotomy and stone removal when the patient can tolerate more extensive treatment, with decompression alone an option when the patient is too unstable for it. Tokyo Guidelines support biliary stenting for cholangitis with coagulopathy and advise individualizing decisions for patients taking antithrombotic agents. In this case, organ dysfunction and warfarin make a staged approach reasonable to discuss, not automatic.
Drainage without sphincterotomy is not guaranteed to work in every anatomy or obstruction. The endoscopist must judge whether cannulation and adequate drainage are likely without sphincterotomy. If not, the team should make a deliberate plan for the safest feasible route rather than discovering mid-procedure that a high-risk intervention was assumed to be unnecessary.
Read INR 3.2 in context
An INR is a measurement of warfarin effect, not a procedural order. A value of 3.2 does not by itself say whether she is within her intended range: the indication and target matter, and the case does not tell us whether she has a mechanical valve, prior stroke, or another high-risk thromboembolic history.
Clarify the documented warfarin indication and target INR, last dose, recent INR trend, prior bleeding or thrombosis, and medication list. Also establish her baseline cognition and functional status so acute confusion is not mistaken for her usual state. These details inform both the urgency of anticoagulation decisions and how soon it may be appropriate to resume treatment.
For planned low-risk endoscopic procedures, BSG/ESGE guidance suggests continuing warfarin when the INR is within the therapeutic range. That guidance does not set a universal acceptable INR for urgent biliary drainage. If this patient’s documented target is 2.0–3.0, an INR of 3.2 is above range; if she has another indication, the target may differ. The endoscopist and anticoagulation team should consider the actual INR and the planned intervention together.
A brief hold of warfarin while the immediate procedural plan is agreed may be reasonable. But holding a dose is not rapid reversal, and waiting several days for the INR to fall is not a source-control strategy in an infected, obstructed duct. Nor is prothrombin complex concentrate (PCC) routinely justified solely to lower the INR for a drainage-only procedure. The procedure-risk category alone does not establish that the procedure can proceed at INR 3.2; the proceduralist must assess that in context.
Reserve rapid reversal for a procedure that requires it
If the endoscopist believes immediate sphincterotomy is necessary, or that adequate drainage cannot otherwise be achieved, the decision changes. The team must weigh the bleeding risk of the intended intervention against the patient’s embolic risk and the harm of delaying source control. If an urgent high-bleeding-risk intervention cannot wait for warfarin effect to fall, four-factor PCC with intravenous vitamin K may be considered under local protocol, with specialist input.
That is a conditional pathway, not an automatic response to INR 3.2. Reversal can carry thrombotic risk, and vitamin K can lengthen the time until warfarin is effective again. Avoid both “reverse everyone” and “never reverse in infection.” Ask the proceduralist which intervention is planned, whether it can be staged, and what INR or hemostatic conditions are needed for that specific plan.
If standard ERCP cannot achieve drainage, involve advanced endoscopy and interventional radiology promptly to consider available alternatives. Coagulopathy is relevant to that choice too; a transhepatic puncture is not a risk-free substitute for endoscopic access. The goal remains timely drainage by a route the team can safely perform.
Close the loop after decompression
A temporary stent buys time; it does not necessarily remove the stone or eliminate the need for definitive biliary care. Before the patient leaves the acute phase, document who will arrange repeat ERCP, when the stent should be reassessed or removed, and how warfarin will be restarted once procedural hemostasis is secure. The restart plan depends on the actual intervention and her thromboembolic risk, not a one-size-fits-all interval.
Common traps are treating every ERCP as a high-bleeding-risk procedure, delaying urgent drainage for a routine warfarin washout, and reversing anticoagulation simply because the INR is flagged. Another trap is treating decompression alone as the required strategy for every patient with cholangitis. The practical correction is to separate source control now from stone clearance when safe, while matching the plan to clinical stability and the actual intervention.
Practical takeaways
- In acute cholangitis, define whether the immediate goal is duct decompression, stone extraction, or both.
- Biliary stenting without sphincterotomy may offer drainage with a different bleeding-risk profile when technically feasible.
- Drainage-only ERCP is a selective option; whether to stage depends on stability, anticoagulation, anatomy, and the proceduralist’s assessment.
- An INR of 3.2 is not, by itself, an indication for PCC or a reason to postpone urgent drainage—but it also does not establish that a procedure can proceed without further assessment.
- If urgent sphincterotomy is unavoidable, individualize reversal and thrombotic-risk assessment with the procedural team.
- Treat temporary drainage as a staged plan: document anticoagulation resumption and definitive follow-up.
